{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"description":"Complete remission (CR) is defined as participants achieving CR defined as \\<5% blasts, \\>1000 neutrophils, \\>100,000 platelets, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.","groups":[{"description":"Participants who were randomized to receive quizartinib treatment regimen.","id":"OG000","title":"Quizartinib"},{"description":"Participants who were randomized to receive placebo treatment regimen.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Complete remission was assessed in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)","title":"Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","type":"SECONDARY","unitOfMeasure":"Participants"}